Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -63,101 | -42,821 | -26,548 | -83,479 | -61,492 |
| Depreciation Amortization | 2,366 | 1,527 | -638 | 2,343 | 1,709 |
| Accounts receivable | 822 | -3,798 | -1,859 | 6,606 | -8,819 |
| Other Working Capital | 1,481 | -169 | 5,515 | 22,103 | 17,487 |
| Other Operating Activity | 11,853 | 11,865 | 5,900 | 3,088 | 16,996 |
| Operating Cash Flow | $-46,579 | $-33,396 | $-17,630 | $-49,339 | $-34,119 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -45,301 | -48,300 | -42,780 | -45,572 | -48,947 |
| PPE Investments | -1,132 | -761 | -411 | -2,297 | -939 |
| Investing Cash Flow | $-46,433 | $-49,061 | $-43,191 | $-47,869 | $-49,886 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 19,985 | N/A |
| Common Stock Issued | 112,030 | 111,235 | 110,034 | 5,079 | 1,996 |
| Financing Cash Flow | $112,030 | $111,235 | $110,034 | $25,064 | $1,996 |
| Beginning Cash Position | 27,357 | 27,357 | 27,357 | 99,501 | 99,501 |
| End Cash Position | 46,375 | 56,135 | 76,570 | 27,357 | 17,492 |
| Net Cash Flow | $19,018 | $28,778 | $49,213 | $-72,144 | $-82,009 |
| Free Cash Flow | |||||
| Operating Cash Flow | -46,579 | -33,396 | -17,630 | -49,339 | -34,119 |
| Capital Expenditure | -1,132 | -761 | -411 | -2,297 | -939 |
| Free Cash Flow | -47,711 | -34,157 | -18,041 | -51,636 | -35,058 |